These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36471407)

  • 1. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
    Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
    World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
    Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
    Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
    Qin H; Wan Y; Dong Y; Sun Q
    Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralsetinib treatment for multiple
    Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
    J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
    Gu L; Ji W; Xu Y; Han Y; Jian H
    Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
    Nguyen L; Monestime S
    Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.].
    Russano M
    Recenti Prog Med; 2021 Jan; 112(1):5e-9e. PubMed ID: 33512366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
    Liao D; Long M; Zhang J; Wei X; Li F; Yan T; Yang D
    Lung Cancer; 2024 Oct; 196():107936. PubMed ID: 39241296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
    Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
    Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
    Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
    Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.
    Lu S; Shen L; Wang Q; Chen H; Zhao Y; Li Y; Segall G; Khanal M; Zhang X; Ding D; Shao J; Pang L
    Adv Ther; 2024 Nov; 41(11):4248-4265. PubMed ID: 39316291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.